Condition: Brest Cancer · Lung Cancer (NSCLC) · Pancreatic Cancer, Adult · Sponsor: Javier Toledo
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. By analysing blood samples using artificial intelligence, the study seeks to create a safe, non-invasive method to enhance cancer diagnosis and monitor treatment responses over time.
This description comes directly from the study's public registry record.
Javier Toledo, Medical Degree · +44 (0)1223 496000 · research@dysplasiadx.com
Osagie Izuogu, PhD · +44 (0)1223 496000 · info@dysplasiadx.com
Always discuss trial participation with your own doctor first.
| Various Cancer Centres | Rosario, Argentina | Active Not Recruiting |
| NSIA- Lagos University Teaching Hospital Cancer Centre | Lagos, Nigeria | Recruiting |
| Babraham Research Institute | Cambridge, United Kingdom | Enrolling By Invitation |
| Dysplasia Diagnostics Limited | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06717295